Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril

International Journal of Cardiology

Volumn 132, Issue 1, 2009, Pages 114-120

  Yokoyama, Jin ^a   Higuma, Takumi ^a   Tomita, Hirofumi ^a   Abe, Naoki ^a   Oikawa, Koichi ^a   Fujiwara, Takayuki ^a   Yokota, Takashi ^a   Yokoyama, Hiroaki ^a   Kimura, Masaomi ^a   Sasaki, Shingo ^a   Hanada, Hiroyuki ^a   Osanai, Tomohiro ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Acute myocardial infarction; In stent restenosis; Telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; ENALAPRIL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PIOGLITAZONE; SULFONYLUREA; TELMISARTAN; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERY DIAMETER; ARTICLE; BARE METAL STENT; BYPASS SURGERY; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG EFFICACY; DRUG FATALITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EMERGENCY SURGERY; FEMALE; FOLLOW UP; HEART REINFARCTION; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; INTIMA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSPECIFIED SIDE EFFECT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CORONARY RESTENOSIS; ENALAPRIL; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; STENTS;

EID: 58949095040     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.11.003     Document Type: Article

References (41)

1. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331 8 (Aug 25 1994) 496-501
2. Carrozza J.P., Kuntz R.E., Fishman R.F., and Baim D.S. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 118 5 (Mar 1 1993) 344-349
3. Klugherz B.D., DeAngelo D.L., Kim B.K., Herrmann H.C., Hirshefeld J.W., and Kolansky D.M. Three-year clinical follow-up after Palmaz-Schatz stenting. J Am Coll Cardiol 27 5 (Apr 1996) 1185-1191
4. Kastrati A., Schomig A., Elezi S., et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30 6 (Nov 15 1997) 1428-1436
5. Law K.W., Ding Z.P., Johdan A., and Lim Y.L. Midterm angiographic outcome of single-vessel intracoronary stent placement in diabetic versus nondiabetic patients: a matched comparative study. Am Heart J 136 1 (Jul 1998) 150-155
6. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med. 327 (1992) 669-677
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
8. Ambrosioni E., Borghi C., and Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N Engl J Med 332 (1995) 80-85
9. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 (1995) 1670-1676
10. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. Circulation 110 5 (Aug 2004) 588-636
11. Forrester J.S., Fishbein M., Helfant R., and Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 17 3 (Mar 1 1991) 758-769 [Review]
12. Kauffman R.F., Bean J.S., Zimmerman K.M., Brown R.F., and Steinberg M.I. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci 49 25 (Nov 18 1991) PL223-PL228
13. Kawamura M., Terashita Z., Okuda H., et al. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 266 3 (Sep 1993) 1664-1669
14. Miyazaki M., Wada T., Shiota N., and Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 13 Suppl 1 (Jan 1999) S21-S25 [discussion S33-S34]
15. Yoshida O., Hirayama H., Nanasato M., Watanabe T., and Murohara T. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J 149 1 (Jan 2005) e2
16. Peters S., Trummel M., Meyners W., Koehler B., and Westermann K. Valsartan versus ACE inhibition after bare metal stent implantation-results of the VALVACE trial. Int J Cardiol 98 2 (Feb 15 2005) 331-335
17. Peters S., Gotting B., Trummel M., Rust H., and Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 13 (2 (Feb 2001) 93-97
18. Takagi T., Yamamuro A., Tamita K., et al. Pioglitazone reduced neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146 2 (Aug 2003) E5
19. Marx N., Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112 18 (Nov 2005) 2792-2798
20. Benson S.C., Pershadsingh H.A., Ho C.I., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 5 (May 2004) 993-1002
21. Takagishi T., Murahashi N., Azagami S., Morimatsu M., and Sasaguri Y. Effect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle cells. Biochem Mol Biol Int 35 2 (Feb 1995) 265-273
22. Naftilan A.J., Pratt R.E., and Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 83 4 (Apr 1989) 1419-1424
23. Itoh H., Mukoyama M., Pratt R.E., Gibbons G.H., and Dzau V.J. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91 5 (May 1993) 2268-2274
24. Clozel J.P., Hess P., Michael C., Schietinger K., and Baumgartner H.R. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension 18 4 Suppl (Oct 1991) II55-II59
25. Powell J.S., Clozel J.P., Muller R.K., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 4914 (Jul 14 1989) 186-188
26. Candipan R.C., Hsiun P.T., Pratt R., and Cooke J.P. Vascular injury augments adrenergic neurotransmission. Circulation 89 2 (Feb 1994) 777-784
27. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation 86 1 (Jul 1992) 100-110
28. Faxon D.P. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 25 2 (Feb 1995) 362-369
29. Meurice T., Bauters C., Hermant X., et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet 357 9265 (Apr 28 2001) 1321-1324
30. Ribichini F., Wijns W., Ferrero V., et al. Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting. Am J Cardiol 91 2 (Jan 15 2003) 154-158
31. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., and Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265 36 (Dec 25 1990) 22348-22357
32. Akasu M., Urata H., Kinoshita A., Sasaguri M., Ideishi M., and Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 32 3 (Sep 1998) 514-520
33. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 6 (Jun 1972) 499-502
34. Goetze S., Xi X.P., Kawano H., et al. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 33 5 (May 1999) 798-806
35. Igarashi M., Takeda Y., Ishibashi N., et al. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm Metab Res 29 9 (Sep 1997) 444-449
36. Igarashi M., Hirata A., Yamaguchi H., et al. Characterization of an inhibitory effect of pioglitazone in balloon-injured vascular smooth muscle cell growth. Metabolism 50 8 (Aug 2001) 955-962
37. Law R.E., Goetze S., Xi X.P., et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101 11 (Mar 21 2000) 1311-1318
38. Marx N., Schonbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor-gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83 11 (Nov 30 1998) 1097-1103
39. Wang C.H., Ciliberti N., Li S.H., et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109 11 (Mar 23 2004) 1392-1400
40. Imayama I., Ichiki T., Inanaga K., et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 72 1 (Oct 1 2006) 184-190
41. Peuler J.D., Phare S.M., Iannucci A.R., and Hodorek M.J. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 9 2 (Feb 1996) 188-192